Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Sponsor
Masonic Cancer Center, University of Minnesota (Other)
Overall Status
Terminated
CT.gov ID
NCT00609739
Collaborator
(none)
1
Enrollment
1
Location
1
Arm
132
Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

RATIONALE: Giving chemotherapy drugs, such as cytarabine and mitoxantrone, before a donor stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When certain stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, and methylprednisolone before or after transplant may stop this from happening.

PURPOSE: This phase I/II trial is studying the side effects and best way to give high-dose cytarabine together with mitoxantrone in treating patients with juvenile myelomonocytic leukemia undergoing a second donor stem cell transplant.

Condition or DiseaseIntervention/TreatmentPhase
Phase 1/Phase 2

Detailed Description

OBJECTIVES:

Primary

  • To determine the incidence of 1-year disease-free survival in patients with juvenile myelomonocytic leukemia and who is undergoing a repeat stem cell transplantation.

Secondary

  • To evaluate the incidence of regimen-related toxicity.

  • To evaluate the incidence of acute and chronic graft-versus-host-disease.

  • To evaluate the incidence of relapse.

OUTLINE:
  • Preparative cytoreductive therapy: Patients receive high-dose cytarabine IV over 2 hours on days -9 to -4 and mitoxantrone hydrochloride IV over 30 minutes on days -9 to -7.

  • Allogeneic hematopoietic stem cell transplantation (HSCT): Patients undergo HSCT on day

  1. Patients undergoing umbilical cord blood transplantation receive methylprednisolone (as graft failure prophylaxis) IV twice daily on days 5 to 19 followed by a taper every other day thereafter until day 25.
  • Graft-versus-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2 hours every 8-12 hours or orally twice daily beginning on day -3 and continuing until day 50, followed by a taper to day 90, in the absence of GVHD. Patients undergoing nongenotypically identical bone marrow transplantation also receive methotrexate IV on day 1 beginning 24 hours after completion of stem cell infusion and on days 3, 6, and
  • Post-transplantation isotretinoin therapy: Patients receive oral isotretinoin once daily beginning on day 60 and continuing until 1 year after HSCT.

Patients undergo bone marrow sample collection on day 21, day 60, day 100, at 6 months, and at 1 year for chimerism studies. Patients also undergo blood sample collection periodically to monitor peripheral blood counts for immune reconstitution.

After completion of study treatment, patients are followed on day 21, day 100, at 6 months, and at 1 year.

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Study Start Date :
Jun 1, 1999
Actual Primary Completion Date :
Jun 1, 2010
Actual Study Completion Date :
Jun 1, 2010

Arms and Interventions

ArmIntervention/Treatment
Experimental: Cytarabine + Mitoxantrone

This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.

Drug: cyclosporine
Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Other Names:
  • CSA
  • Drug: cytarabine
    3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
    Other Names:
  • Ara-C
  • Drug: filgrastim
    Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
    Other Names:
  • G-CSF
  • Drug: methotrexate
    MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
    Other Names:
  • MTX
  • Drug: methylprednisolone
    Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
    Other Names:
  • Medrol
  • Drug: mitoxantrone hydrochloride
    10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
    Other Names:
  • Mitoxantrone
  • Procedure: allogeneic bone marrow transplantation
    Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.

    Procedure: umbilical cord blood transplantation
    Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.

    Drug: Cis-Retinoic acid
    Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
    Other Names:
  • isotretinoin
  • Outcome Measures

    Primary Outcome Measures

    1. Disease-free Survival [1 year]

      Number of patients who were free of disease and alive at 1 year.

    Secondary Outcome Measures

    1. Patients With Regimen-Related Toxicity [Up to 30 Days Post Study Treatment]

      Number of patients with adverse events related to treatment.

    2. Patients With Graft-Versus-Host-Disease [Up to 30 Days Post Study Treatment]

      Number of patients who exhibited acute and/or chronic graft-versus-host disease.

    3. Patients Who Relapsed [1 Year]

      Number of patients whose disease relapsed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 18 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients age 0-18 with juvenile myelomonocytic leukemia (JMML) who have relapsed or have residual disease after allogeneic HCT. Residual disease is defined as failure to eradicate original disease without prior documentation of remission. Relapse is defined as reappearance of i) leukocytosis with absolute monocytosis >1 x 10^8/L, ii) presence of immature myeloid cells in the peripheral circulation in two consecutive bone marrow specimens taken at least one month apart, or iii) presence of clonal cytogenetic abnormality. The diagnosis of relapse will be supported by the return of an abnormal cytogenetic marker (if present at diagnosis) or the presence of host cells by RFLP or other method.

    • Patients should be at least 6 months from first hematopoietic cell transplant (HCT) if clinically stable. (If JMML is rapidly progressive, second HCT may be performed earlier).

    • Adequate major organ function including:

    • Cardiac: ejection fraction ≥45%

    • Pulmonary: FEV >50%, DLCO >50%

    • Renal: creatinine clearance ≥40 mL/min

    • Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)

    • Karnofsky performance status ≥70% or Lansky score ≥50%

    • Written informed consent.

    Exclusion Criteria:
    • Active uncontrolled infection within one week of HCT.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Masonic Cancer Center at University of MinnesotaMinneapolisMinnesotaUnited States55455

    Sponsors and Collaborators

    • Masonic Cancer Center, University of Minnesota

    Investigators

    • Principal Investigator: Margaret L. MacMillan, MD, Masonic Cancer Center, University of Minnesota

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Masonic Cancer Center, University of Minnesota
    ClinicalTrials.gov Identifier:
    NCT00609739
    Other Study ID Numbers:
    • 1999LS032
    • UMN-MT1999-08
    • 9906M07303
    First Posted:
    Feb 7, 2008
    Last Update Posted:
    Dec 28, 2017
    Last Verified:
    Dec 1, 2017

    Study Results

    Participant Flow

    Recruitment DetailsOnly 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.
    Pre-assignment Detail
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Period Title: Overall Study
    STARTED1
    COMPLETED1
    NOT COMPLETED0

    Baseline Characteristics

    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Overall Participants1
    Age (Count of Participants)
    <=18 years
    1
    100%
    Between 18 and 65 years
    0
    0%
    >=65 years
    0
    0%
    Sex: Female, Male (Count of Participants)
    Female
    1
    100%
    Male
    0
    0%
    Region of Enrollment (participants) [Number]
    United States
    1
    100%

    Outcome Measures

    1. Primary Outcome
    TitleDisease-free Survival
    DescriptionNumber of patients who were free of disease and alive at 1 year.
    Time Frame1 year

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Measure Participants1
    Number [Participants]
    0
    0%
    2. Secondary Outcome
    TitlePatients With Regimen-Related Toxicity
    DescriptionNumber of patients with adverse events related to treatment.
    Time FrameUp to 30 Days Post Study Treatment

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Measure Participants1
    Number [participants]
    0
    0%
    3. Secondary Outcome
    TitlePatients With Graft-Versus-Host-Disease
    DescriptionNumber of patients who exhibited acute and/or chronic graft-versus-host disease.
    Time FrameUp to 30 Days Post Study Treatment

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Measure Participants1
    Number [participants]
    1
    100%
    4. Secondary Outcome
    TitlePatients Who Relapsed
    DescriptionNumber of patients whose disease relapsed.
    Time Frame1 Year

    Outcome Measure Data

    Analysis Population Description
    [Not Specified]
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    Measure Participants1
    Number [participants]
    1
    100%

    Adverse Events

    Time FrameUp to 30 days post study treatment.
    Adverse Event Reporting Description Regimen related toxicity (RRT) is a concern, but because of the seriousness of relapsed JMML, a high incidence of grade III and IV RRT will be considered acceptable. No other adverse events were collected.
    Arm/Group TitleCytarabine + Mitoxantrone
    Arm/Group DescriptionPatients receive administration of high dose cytosine arabinoside and mitoxantrone followed by hematopoietic cell transplant.
    All Cause Mortality
    Cytarabine + Mitoxantrone
    Affected / at Risk (%)# Events
    Total/ (NaN)
    Serious Adverse Events
    Cytarabine + Mitoxantrone
    Affected / at Risk (%)# Events
    Total1/1 (100%)
    General disorders
    Death1/1 (100%) 1
    Other (Not Including Serious) Adverse Events
    Cytarabine + Mitoxantrone
    Affected / at Risk (%)# Events
    Total0/1 (0%)

    Limitations/Caveats

    Only 1 patient was enrolled (yr 1999) and later died (yr 2000). Study was terminated due to low accrual.

    More Information

    Certain Agreements

    All Principal Investigators ARE employed by the organization sponsoring the study.

    There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

    Results Point of Contact

    Name/TitleMargaret MacMillan, M.D.
    OrganizationMasonic Cancer Center, University of Minnesota
    Phone612-626-2778
    Emailmacmi002@umn.edu
    Responsible Party:
    Masonic Cancer Center, University of Minnesota
    ClinicalTrials.gov Identifier:
    NCT00609739
    Other Study ID Numbers:
    • 1999LS032
    • UMN-MT1999-08
    • 9906M07303
    First Posted:
    Feb 7, 2008
    Last Update Posted:
    Dec 28, 2017
    Last Verified:
    Dec 1, 2017